血小板减少患者皮下注射重组人血小板生成素后抗体生成的动态监测  

Development of Recombinant Human Thrombopoietin Antibodies Following Multi -Dosing, Subcutaneously Medication in Thrombocytopenic Patients

作　　者：华宝来[1] 赵永强[1] 朱铁楠[1] 范连凯[1] 王书杰[1] 潘家绮[1] 

机构地区：[1]中国医学科学院

出　　处：《血栓与止血学》2005年第2期59-61,共3页Chinese Journal of Thrombosis and Hemostasis

摘　　要：目的监测各种化疗相关性血小板减少和慢性难治性血小板减少性紫癜患者注射重组人血小板生成素(rhTPO)后抗rhTPO抗体的生成。方法于rhTPO给药前及给药第7、14、21、28、35 d取血,采用ELISA法检测血清抗rhTPO抗体。通过观察阳性血清对依赖TPO的TD3细胞体外增殖的影响,判断抗体是否具有中和rhTPO的活性。结果81例中有3例(3.7%)用药第14、21或第21、28 d的血清抗体检测阳性,滴度均1:5。中和性试验表明该抗体不具有中和rhTPO的活性。结论　血小板减少患者多次皮下注射rhTPO后体内可出现低滴度抗rhTPO非中和抗体。Objective To observe the development of recombinant human thrombopoietin ( rhTPO) antibodies following multi-dosing,subcutaneously adminstration of rhTPO in the patients with chemotherapy-in-daced thrombocytopenia or chronic refractory idiopathic thrombocytopenic purpura ( ITP). Methods Sera from the patients were obtained before rhTPO adminstration and on day 7,14,21,28 and 35 after the medication. Anti-rhTPO antibody was detected with ELISA. The neutralizing activity of the antibody was determined with in vitro proliferation inhibitory experiment using TPO-dependent cell line,TD3 cells. Results Low titers (1:5) of anti-rhTPO antibody were detected with ELISA in the sera on day 14,21 or 28 from 3 (4% ) out of 81 patients. Neutralizing test showed that the antibody was no neutralizing acticity on rhTPO. Conclusion Low titers of non-neutralizing anti-rhTPO antibody may develop in the thrombocytopenic patienls receiving multi-dosing, subcutaneous rhTPO.

关 键 词：血小板减少性紫癜 重组人血小板生成素 抗体 

分 类 号：R558.2[医药卫生—血液循环系统疾病]